Natale Daniele Brunetti1, Francesco Santoro2, Luisa De Gennaro3, Michele Correale4, Antonio Gaglione5, Matteo Di Biase5. 1. Ospedali Riuniti University Hospital, University of Foggia, Foggia, Italy; Department of Medical & Surgical Sciences, University of Foggia, Italy. Electronic address: natale.brunetti@unifg.it. 2. Asklepios Klinik Sankt Georg, Hamburg, Germany. 3. Ospedale San Paolo, Bari, Italy. 4. Ospedali Riuniti University Hospital, University of Foggia, Foggia, Italy. 5. Ospedali Riuniti University Hospital, University of Foggia, Foggia, Italy; Department of Medical & Surgical Sciences, University of Foggia, Italy.
Abstract
BACKGROUND: In a recent paper Singh et al. analyzed the effect of drug treatment on recurrence of takotsubo cardiomyopathy (TTC) in a comprehensive meta-analysis. The study found that recurrence rates were independent of clinic utilization of BB prescription, but inversely correlated with ACEi/ARB prescription: authors therefore conclude that ACEi/ARB rather than BB may reduce risk of recurrence. METHODS: We aimed to re-analyze data reported in the study, now weighted for populations' size, in a meta-regression analysis. RESULTS: After multiple meta-regression analysis, we found a significant regression between rates of prescription of ACEi and rates of recurrence of TTC; regression was not statistically significant for BBs. CONCLUSIONS: On the bases of our re-analysis, we confirm that rates of recurrence of TTC are lower in populations of patients with higher rates of treatment with ACEi/ARB. That could not necessarily imply that ACEi may prevent recurrence of TTC, but barely that, for example, rates of recurrence are lower in cohorts more compliant with therapy or more prescribed with ACEi because more carefully followed. Randomized prospective studies are surely warranted.
BACKGROUND: In a recent paper Singh et al. analyzed the effect of drug treatment on recurrence of takotsubo cardiomyopathy (TTC) in a comprehensive meta-analysis. The study found that recurrence rates were independent of clinic utilization of BB prescription, but inversely correlated with ACEi/ARB prescription: authors therefore conclude that ACEi/ARB rather than BB may reduce risk of recurrence. METHODS: We aimed to re-analyze data reported in the study, now weighted for populations' size, in a meta-regression analysis. RESULTS: After multiple meta-regression analysis, we found a significant regression between rates of prescription of ACEi and rates of recurrence of TTC; regression was not statistically significant for BBs. CONCLUSIONS: On the bases of our re-analysis, we confirm that rates of recurrence of TTC are lower in populations of patients with higher rates of treatment with ACEi/ARB. That could not necessarily imply that ACEi may prevent recurrence of TTC, but barely that, for example, rates of recurrence are lower in cohorts more compliant with therapy or more prescribed with ACEi because more carefully followed. Randomized prospective studies are surely warranted.
Authors: Bala Pushparaji; Teodora Donisan; Dinu V Balanescu; Nicolas Palaskas; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Saamir A Hassan; Konstantinos Dean Boudoulas; Konstantinos Marmagkiolis; Ludhmila Abrahao Hajjar; Cezar A Iliescu Journal: Curr Oncol Rep Date: 2021-09-27 Impact factor: 5.075
Authors: Sara Moscatelli; Fabrizio Montecucco; Federico Carbone; Alberto Valbusa; Laura Massobrio; Italo Porto; Claudio Brunelli; Gian Marco Rosa Journal: Biomed Res Int Date: 2019-10-30 Impact factor: 3.411